Date: 2013-02-01
Type of information: Grant
Company: Antabio (France)
Investors: Wellcome Trust (UK)
Amount: €4.7 million
Funding type: grant
Planned used: The Trust has awarded Antabio €4.7m over 3 years to fund the development of a novel, safe and efficacious pan-inhibitor of bacterial metallo ß-lactamases, from current leads to preclinical candidate nomination. The project team, led by Principal Investigator Dr. Marc Lemonnier CEO of Antabio, will develop drugs inhibiting these MBL enzymes, thereby returning carbapenems to full clinical effectiveness.
Others: * On March 7, 2016. Antabio announced that it has achieved two milestones in its antibacterial drug discovery collaborations with the Wellcome Trust. These results release a further €3.1 million from the Seeding Drug Discovery Awards received by Antabio. The first collaboration (“the MBLi program”) began in February 2013 when the Wellcome Trust awarded Antabio €4.7 million to fund the discovery of a novel, safe and efficacious inhibitor of bacterial metallo beta-lactamases (MBLs). Antabio has identified a highly-active in vivo lead series with drug-like features and MBL coverage against clinical isolates including NDM variants. These results mark a key milestone in the MBLi collaboration with the Wellcome Trust which aims to nominate a preclinical development candidate by Q1 2017. * On February 1, 2013, Antabio has received a €4.7 Million Wellcome Trust Seeding Drug Discovery Award to develop novel small molecule drugs for the treatment of life-threatening infections caused by multi-drug resistant Gram-negative bacteria.
Therapeutic area: Infectious diseases
